Sequential galactosyltransferase and carcinoembryonic antigen levels in advanced breast carcinoma

Joseph F. Paone, R. Robinson Baker, T. Phillip Waalkes, Joel H. Shaper

Research output: Contribution to journalArticle

Abstract

UDP-galactosyltransferase (GT), an enzyme that functions in the biosynthesis of glycoproteins, has recently been found to be a sensitive biologic tumor marker. In the present study, sequential GT levels were compared to simultaneous CEA determinations to establish which biomarker more accurately reflects changes in tumor activity in patients receiving therapy for advanced breast carcinoma. Serum levels of GT and CEA were measured each month in 38 patients undergoing combination chemotherapy for metastatic breast carcinoma. The results were correlated with the objective responses observed to chemotherapy during this period. Prior to the institution of chemotherapy, significant serum GT elevations were observed in 84.2% ( 32 38) of the patients, while 55.3% ( 21 38) had elevations in levels of CEA. During therapy 71.4% ( 10 14) and 50% ( 7 14) of the GT and CEA levels, respectively, decreased in patients who had an objective response to therapy. In the patients whose disease progressed on therapy, 75% ( 18 24) had significant increases in GT levels during this interval, while 41.6% ( 10 24) had increases in CEA (P <0.01). Furthermore, in 11 patients (29.5%) serum GT alterations correctly reflected changes in tumor activity, while CEA levels remain static. These data indicate that GT is more sensitive than CEA as a marker for breast carcinoma and suggest that GT may be clinically useful in the management of patients with metastatic breast disease.

Original languageEnglish (US)
Pages (from-to)269-273
Number of pages5
JournalJournal of Surgical Research
Volume31
Issue number4
DOIs
StatePublished - 1981

Fingerprint

Galactosyltransferases
Carcinoembryonic Antigen
Breast Neoplasms
Serum
Drug Therapy
Breast Diseases
Uridine Diphosphate
Therapeutics
Tumor Biomarkers
Combination Drug Therapy
Neoplasms
Glycoproteins
Biomarkers

ASJC Scopus subject areas

  • Surgery

Cite this

Sequential galactosyltransferase and carcinoembryonic antigen levels in advanced breast carcinoma. / Paone, Joseph F.; Baker, R. Robinson; Phillip Waalkes, T.; Shaper, Joel H.

In: Journal of Surgical Research, Vol. 31, No. 4, 1981, p. 269-273.

Research output: Contribution to journalArticle

Paone, Joseph F. ; Baker, R. Robinson ; Phillip Waalkes, T. ; Shaper, Joel H. / Sequential galactosyltransferase and carcinoembryonic antigen levels in advanced breast carcinoma. In: Journal of Surgical Research. 1981 ; Vol. 31, No. 4. pp. 269-273.
@article{3b90dc8e49fd4b7995a6e81412f2514b,
title = "Sequential galactosyltransferase and carcinoembryonic antigen levels in advanced breast carcinoma",
abstract = "UDP-galactosyltransferase (GT), an enzyme that functions in the biosynthesis of glycoproteins, has recently been found to be a sensitive biologic tumor marker. In the present study, sequential GT levels were compared to simultaneous CEA determinations to establish which biomarker more accurately reflects changes in tumor activity in patients receiving therapy for advanced breast carcinoma. Serum levels of GT and CEA were measured each month in 38 patients undergoing combination chemotherapy for metastatic breast carcinoma. The results were correlated with the objective responses observed to chemotherapy during this period. Prior to the institution of chemotherapy, significant serum GT elevations were observed in 84.2{\%} ( 32 38) of the patients, while 55.3{\%} ( 21 38) had elevations in levels of CEA. During therapy 71.4{\%} ( 10 14) and 50{\%} ( 7 14) of the GT and CEA levels, respectively, decreased in patients who had an objective response to therapy. In the patients whose disease progressed on therapy, 75{\%} ( 18 24) had significant increases in GT levels during this interval, while 41.6{\%} ( 10 24) had increases in CEA (P <0.01). Furthermore, in 11 patients (29.5{\%}) serum GT alterations correctly reflected changes in tumor activity, while CEA levels remain static. These data indicate that GT is more sensitive than CEA as a marker for breast carcinoma and suggest that GT may be clinically useful in the management of patients with metastatic breast disease.",
author = "Paone, {Joseph F.} and Baker, {R. Robinson} and {Phillip Waalkes}, T. and Shaper, {Joel H.}",
year = "1981",
doi = "10.1016/0022-4804(81)90048-2",
language = "English (US)",
volume = "31",
pages = "269--273",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "4",

}

TY - JOUR

T1 - Sequential galactosyltransferase and carcinoembryonic antigen levels in advanced breast carcinoma

AU - Paone, Joseph F.

AU - Baker, R. Robinson

AU - Phillip Waalkes, T.

AU - Shaper, Joel H.

PY - 1981

Y1 - 1981

N2 - UDP-galactosyltransferase (GT), an enzyme that functions in the biosynthesis of glycoproteins, has recently been found to be a sensitive biologic tumor marker. In the present study, sequential GT levels were compared to simultaneous CEA determinations to establish which biomarker more accurately reflects changes in tumor activity in patients receiving therapy for advanced breast carcinoma. Serum levels of GT and CEA were measured each month in 38 patients undergoing combination chemotherapy for metastatic breast carcinoma. The results were correlated with the objective responses observed to chemotherapy during this period. Prior to the institution of chemotherapy, significant serum GT elevations were observed in 84.2% ( 32 38) of the patients, while 55.3% ( 21 38) had elevations in levels of CEA. During therapy 71.4% ( 10 14) and 50% ( 7 14) of the GT and CEA levels, respectively, decreased in patients who had an objective response to therapy. In the patients whose disease progressed on therapy, 75% ( 18 24) had significant increases in GT levels during this interval, while 41.6% ( 10 24) had increases in CEA (P <0.01). Furthermore, in 11 patients (29.5%) serum GT alterations correctly reflected changes in tumor activity, while CEA levels remain static. These data indicate that GT is more sensitive than CEA as a marker for breast carcinoma and suggest that GT may be clinically useful in the management of patients with metastatic breast disease.

AB - UDP-galactosyltransferase (GT), an enzyme that functions in the biosynthesis of glycoproteins, has recently been found to be a sensitive biologic tumor marker. In the present study, sequential GT levels were compared to simultaneous CEA determinations to establish which biomarker more accurately reflects changes in tumor activity in patients receiving therapy for advanced breast carcinoma. Serum levels of GT and CEA were measured each month in 38 patients undergoing combination chemotherapy for metastatic breast carcinoma. The results were correlated with the objective responses observed to chemotherapy during this period. Prior to the institution of chemotherapy, significant serum GT elevations were observed in 84.2% ( 32 38) of the patients, while 55.3% ( 21 38) had elevations in levels of CEA. During therapy 71.4% ( 10 14) and 50% ( 7 14) of the GT and CEA levels, respectively, decreased in patients who had an objective response to therapy. In the patients whose disease progressed on therapy, 75% ( 18 24) had significant increases in GT levels during this interval, while 41.6% ( 10 24) had increases in CEA (P <0.01). Furthermore, in 11 patients (29.5%) serum GT alterations correctly reflected changes in tumor activity, while CEA levels remain static. These data indicate that GT is more sensitive than CEA as a marker for breast carcinoma and suggest that GT may be clinically useful in the management of patients with metastatic breast disease.

UR - http://www.scopus.com/inward/record.url?scp=0019409174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019409174&partnerID=8YFLogxK

U2 - 10.1016/0022-4804(81)90048-2

DO - 10.1016/0022-4804(81)90048-2

M3 - Article

VL - 31

SP - 269

EP - 273

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 4

ER -